Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acromegaly.

Philippe Chanson1, Sylvie Salenave

  • 1Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France. philippe.chanson@bct.aphp.fr

Orphanet Journal of Rare Diseases
|June 27, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The renin-angiotensin system is activated by short-term, but repressed by long-term growth hormone excess.

European journal of endocrinology·2026
Same author

How genetic/genomic/epigenetic changed or will change the diagnosis and management of endocrine disorders?

Annales d'endocrinologie·2026
Same author

Comment la génétique, la génomique et l'épigénétique ont déjà changé ou vont changer le diagnostic et la prise en charge des maladies endocriniennes ?

Annales d'endocrinologie·2026
Same author

Genotype-phenotype correlation and challenges in mutation detection in McCune-Albright syndrome: A retrospective study of a French cohort.

Annales d'endocrinologie·2026
Same author

Acromegaly diagnosis.

The Journal of clinical endocrinology and metabolism·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same journal

A lifespan pooled analysis of 832 cases: characterizing the lifespan profile of clinical presentations and comorbidities in congenital pulmonary airway malformation.

Orphanet journal of rare diseases·2026
Same journal

Mortality trends and socioeconomic inequalities in sickle cell disease in Colombia, 2012-2023: a population-based study.

Orphanet journal of rare diseases·2026
Same journal

Mitochondrial stress markers associate with phenotypic variability in Fabry disease.

Orphanet journal of rare diseases·2026
Same journal

Preclinical modeling of Loeys-Dietz syndrome: insights into mechanisms and therapy.

Orphanet journal of rare diseases·2026
Same journal

Fatigue and pain in children with multiple osteochondromas: a cross-sectional study.

Orphanet journal of rare diseases·2026
Same journal

Health service access and delivery for people living with rare disorders: a scoping review.

Orphanet journal of rare diseases·2026
See all related articles

Acromegaly, a disorder of excess growth hormone (GH), causes physical changes and health issues. Early diagnosis and treatment, often with surgery or medication, can normalize hormone levels and life expectancy, though some long-term effects may persist.

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Acromegaly results from excessive growth hormone (GH) production, typically due to a pituitary adenoma.
  • It leads to progressive somatic disfigurement and serious systemic complications.
  • Diagnosis is often delayed due to insidious onset, affecting middle-aged adults.

Purpose of the Study:

  • To summarize the clinical features, diagnosis, and management of acromegaly.
  • To highlight the impact of GH and IGF-I levels on patient prognosis.
  • To discuss treatment strategies and their effectiveness in achieving hormonal control and improving life expectancy.

Main Methods:

  • Biochemical confirmation using oral glucose tolerance test (OGTT) for GH and serum IGF-I levels.
  • Imaging studies (e.g., MRI) to assess pituitary adenoma size and extension.

Related Experiment Videos

  • Echocardiography and sleep apnea testing to evaluate systemic impact.

    • Main Results:

    • Treatment, including transsphenoidal surgery, somatostatin analogs, radiotherapy, or GH antagonists, aims to normalize GH and IGF-I.
    • Successful treatment can normalize life expectancy.
    • Despite hormonal control, residual sequelae like joint pain and deformities can affect quality of life.

    Conclusions:

    • Acromegaly requires timely diagnosis and comprehensive management to mitigate systemic complications.
    • Multimodal treatment strategies are effective in controlling hormonal hypersecretion.
    • Long-term follow-up is essential to manage persistent sequelae and ensure optimal patient outcomes.